Myrtelle to Showcase Gene Therapy Progress for Canavan Disease at ASGCT 2026
Myrtelle, Inc., a clinical-stage gene therapy company, will present clinical trial data for its MYR-101 gene therapy program at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The program targets Canavan disease, a rare neurodegenerative disorder. Dr. Paola Leone will present data showing therapeutic benefits and clinical improvements in treated children. The company is also advancing its regulatory path toward a Biologics License Application (BLA) submission, in collaboration with its manufacturing partner, Viralgen. 
